Engineering antibody-based molecules for HIV treatment and cure

Area of Science:

• Immunology
• Virology
• Biotechnology

Background:

• Current antiretroviral therapies for HIV-1 have limitations in addressing viral diversity and latent reservoirs.
• Effective immunotherapy must enhance the immune system's capacity to target persistent HIV-1.
• Antibody-based strategies offer a promising avenue for novel HIV-1 immunotherapeutics.

Purpose of the Study:

• To review and discuss the requirements for novel immunotherapeutic molecules as alternatives to current antiretroviral therapies.
• To explore the design and potential of multispecific antibody-based molecules for HIV-1 treatment.
• To stimulate discussion on future directions in HIV-1 immunotherapy.

Main Methods:

• Review of engineered antibody-based molecules, including bispecific and trispecific antibodies.
• Analysis of antibody structures (IgG-like and non-IgG-like) and their mechanisms of action.
• Evaluation of in vitro and in vivo data for promising antibody-based candidates.

Main Results:

• Bispecific and trispecific antibodies target multiple HIV-1 envelope epitopes, increasing neutralization potency and breadth.
• These engineered antibodies enhance avidity for the HIV-1 envelope.
• Antibody molecules engaging cellular receptors facilitate immune effector cell engagement and elimination of infected cells.

Conclusions:

• Engineered antibody-based molecules demonstrate potential for HIV-1 treatment.
• Multispecific antibodies offer improved neutralization and effector functions.
• Novel antibody designs show promise in vitro and in vivo for combating HIV-1.